NeOnc Technologies Holdings, Inc. Files Amended 10-K/A: Key Details for Investors

Overview

NeOnc Technologies Holdings, Inc. (“NeOnc” or the “Company”), a pharmaceutical preparations company listed on the Nasdaq Global Market under the symbol NTHI, has filed Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. This amendment was filed to include information previously omitted in reliance on SEC rules, specifically Items 10 through 14 of Part III of Form 10-K, which relates to directors, executive compensation, security ownership, related party transactions, and additional disclosures.

Key Highlights & Potentially Price-Sensitive Information

• Correction of Financial Statement Error: The Company disclosed that the financial statements included in this filing reflect the correction of an error to previously issued financial statements. While the correction did not require a compensation clawback for executives, the necessity of a restatement is material and may impact investor confidence and share value.
• Executive Compensation Structure:
  • The CEO, COO, and CFO received significant base salaries in 2024 (\$212,000 for COO, \$195,000 for CFO, and \$179,000 for CEO), but no bonuses or option awards were issued in the reported year. Several grants of restricted stock with performance and time-based vesting were made, reflecting a strong equity-based incentive structure.
  • Notably, in January 2024, 800,000 restricted shares were granted to Dr. Thomas C. Chen (CEO), with two-thirds time vested and one-third performance-based. Similar equity awards were granted to other executives, including Josh Neman (200,000 shares in June 2025) and David Suh (170,000 shares in March 2026).
  • Vesting of these restricted stock awards was subject to the Company’s Nasdaq listing, and thus not recognized as issued as of December 31, 2024. Investors should monitor these awards as future expenses and potential dilution as they vest.
• Advances & Related Party Transactions:
  • In February 2025, Executive Chairman Amir Heshmatpour advanced \$300,000 to the Company, with a 100% original issue discount (OID)—meaning he is to receive \$600,000 upon repayment, equating to a highly favorable interest arrangement for the insider. In the event of default, interest increases to 10% per annum. This arrangement, while providing liquidity, is highly dilutive and could raise governance concerns among investors.
  • The Company also maintains a receivable of \$138,247 from HCWG LLC and issued 162,500 shares in April 2025 following the cashless exercise of a warrant related to credit facilities. Such related party transactions should be scrutinized for potential conflicts of interest.
• Clawback Policy: The board adopted an incentive compensation clawback policy, in line with NASDAQ requirements, which mandates the recovery of excess incentive compensation paid to current and former executive officers in the event of a material financial restatement. This is a positive signal to shareholders regarding accountability and governance.
• Equity Plan and Dilution: As of the report, the only compensation plan in place is the 2023 Incentive Stock Plan, with 419,507 shares available for future grants under non-security-holder-approved plans. No options were outstanding at the time of reporting, but significant restricted stock remains to vest, which could dilute current shareholders.
• Director and Officer Compliance: Several late filings (Form 3 and 4) were reported for directors and officers in 2025, which may raise minor governance and compliance concerns, though the Company asserts all filings are now current.
• Audit and Governance:
  • The audit committee is comprised entirely of independent directors, with Bader Almonawer serving as the financial expert. This strengthens oversight and should reassure investors regarding financial controls.
  • The company has adopted a Code of Ethics and Insider Trading Policy applicable to all directors, officers, and employees.
• Outstanding Shares and Major Holders:
  • As of May 4, 2026, there were 25,285,530 shares of common stock outstanding. The largest reported beneficial owner (>5%) is Cinctive Global Master Fund Ltd., though the exact holding was not specified in the summary tables.
  • Other material holders include Neucen Biomedical Co. LTD and Orion Biotech, as well as various individual insiders and affiliates.
• Audit Fees: Audit fees for 2025 and 2024 were \$304,622 and \$322,905, respectively. There were no audit-related fees or work performed by non-permanent employees of the principal auditor.

Additional Details for Shareholders

• There are no family relationships among executive officers and directors, and no director or officer was implicated in material legal proceedings in the last ten years.
• All related party transactions must be approved by the Audit Committee, with the Compensation and Governance Committees involved for executive and director contracts. The Company asserts that all insider transactions are reviewed for fairness and to avoid conflicts of interest.
• The Company is classified as a non-accelerated filer, smaller reporting company, and an emerging growth company, opting out of the extended transition period for new or revised accounting standards.

What Could Move the Share Price?

• Financial Restatement: The correction of a previously issued financial statement error is a material event that could impact investor sentiment and the share price, particularly if it raises concerns regarding internal controls or future restatements.
• Insider-Related Financing: The highly favorable advances made by the Executive Chairman could be viewed as both a vote of confidence and a governance risk, depending on investor perspective.
• Large Unvested Equity Grants: Significant restricted stock awards to executives could result in future dilution and may affect the share price as they vest, especially if performance conditions are met.
• Governance Enhancements: The adoption of a robust clawback policy and the maintenance of an independent audit committee are positive signals, potentially supporting share value by improving investor confidence in governance practices.

Conclusion

NeOnc Technologies Holdings, Inc.’s amended 10-K/A reveals several key items for shareholders, including a material financial restatement, significant insider financing arrangements, and potential future dilution from executive equity grants. The Company has taken steps to strengthen governance practices, though investors should remain alert to the effects of related party transactions and the timing of equity award vesting. These factors, collectively, may impact the Company’s share price in the near to medium term.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own due diligence and consult with professional advisors before making investment decisions. The information is based on the Company’s SEC filing (Form 10-K/A for the fiscal year ended December 31, 2025) and is believed to be accurate as of the date of publication, but no warranty is given as to its completeness or accuracy.

View NEONC TECHNOLOGIES HOLDINGS, INC. Historical chart here